Understanding the epidemiology and burden of antimicrobial resistance (AMR) is crucial for formulating effective public health strategies. This session will delve into the trends, regional variations and future projections of AMR – highlighting the importance of comprehensive data and targeted interventions.
28 October 2024, 17:00 - 18:00 CET
Moderators: Anna Both, Christian Kraef
Accurate and timely diagnosis is a cornerstone in the fight against AMR. This session will explore the challenges and innovations in diagnostic tools, especially in resource-limited settings, but also the importance of surveillance. It will also address global initiatives aimed at reducing diagnostic inequalities to improve AMR management worldwide.
6 November 2024, 17:00 - 18:00 CET
Moderators: Sara Tomczyk, Claudio Neidhöfer
The development of new antibiotics and the optimisation of existing treatments are vital to counter the growing threat of AMR. This session will cover the latest strategies in antibiotic development, the challenges faced in different phases of drug development, and the efforts to improve diagnosis and treatment of antibiotic-resistant infections.
13 November 2024, 15:30 - 16:30 CET
Moderators: Tomislav Mestrovic, Giorgia Caruana
This session will be in collaboration with the International Society for Infectious Diseases (ISID)
Global collaboration and policy-making are essential to effectively combat AMR. This session will discuss the strategic directions from the policy-makers, the specific needs of low- and lower-middle-income countries (LMICs), as well as the potential role of vaccines in reducing AMR. The focus will be on actionable policies and collaborative efforts to address this global health challenge.
20 November 2024, 17:00 - 18:30 CET
Moderators: Holger Rohde, Nicholas Power
Moderators: Holger Rohde, Giorgia Caruana
Moderators: Anna Both, Claudio Neidhöfer
There is a concerning recent emergence of a hypervirulent Klebsiella pneumoniae exhibiting extensive or panresistant phenotype through acquisition of carbapenemase-encoding elements. Between the two ECDC risk assessments in March 2021 and February 2024 the number of EU/EEA countries reporting cases increased from 4 to 10, with the total number of reported cases increasing from 12 to 143. Despite control efforts, there is now evidence of sustained spread of a specific lineage of hypervirulent carbapenemase-producing K. pneumoniae, i.e. ST23-K1, in one European country (Ireland) as well as potential within-country transmission in three other European countries (France, Latvia, and Lithuania) although epidemiological data to confirm this were missing.
Links
A new report from the Global Leaders Group (GLG) on AMR outlines 10 policy recommendations for consideration at the UN General Assembly High-level Meeting on AMR in September 2024.